Clinical Trials, Blood Products & Alternative Therapies

We are continuously adding new resource links to help ensure this page remains a hub of information to the TTP community. If you come across an informative source on the web, please let us know so that we can add it for others to easily find.

Articles are listed for your convenience. We do not endorse or recommend the contents.

Title  Description
Caplacizumab Phase III Trial (HERCULES) The study is a phase III, double blind, placebo-controlled, randomized study to evaluate the efficacy and safety of caplacizumab treatment. "Conclusions: Among patients with TTP, treatment with caplacizumab was associated with faster normalization of the platelet count; a lower incidence of a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the treatment period; and a lower rate of recurrence of TTP during the trial than placebo."
Study about living with hTTP This research may help improve how the patient’s experience is accounted for in clinical trials for new treatments, and may also lead to interventions designed to better support patients and their families going through the treatment experience.
OMS721 Report OMS721 demonstrates activity in thrombotic microangiopathies. (August 2015)
The Hereditary TTP Registry Genotype and phenotype correlation in hereditary Thrombotic Thrombocytopenic Purpura.
Research & Markets: TTP Pipeline Insights 2015 This report covers the TTP pipeline molecules at various stages of development.
Boy's severe peanut, fish allergies traced to blood transfusion CBC News Health - April 7, 2015
Omeros Trial Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies. November, 2014.
Clinical listing for TTP Click to learn more about current trials. It is hard to approve new treatments for rare disorders like TTP. Read up on treatment opportunities to stay informed and participate as you and your health care professional see fit.
Efficacy & Safety of Rituximab Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. (Dec 2010)
NAC Treatment Opportunity Thrombotic thrombocytopenic purpura: reducing the risk? (Feb 2011)
Recombinant ADDAMTS13 Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. (May 2011)
Rituximab Rituximab in Patients with relapsed or refractory TTP - HUS (Oct 2009)
Solvent Detergent Plasma Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. (Aug 2007)
Solvent Detergent Plasma Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience (Jan 2010)
Solvent/detergent-treated human plasma (SDP) CADTH recomendation CADTH recommends restricted access for SDP in Canada as an alternative to frozen plasma. This recommendation includes the use of SDP for a subset of TTP patients. (May 2011)
Transfusion News Video from Transfusion News regarding current and emerging TTP treatment options - use of Rituximab and corticosteroids at initial presentation and to maintain remission.
Clinical Listing for TTP Registry Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) (TTP registry)
Hereditary Thrombotic Thrombocytopenic Purpura and the hereditary TTP registry Hereditary Thrombotic Thrombocytopenic Purpura and the hereditary TTP registry (May 2013)
Solvent Detergent Plasma Octapharma USA Announces Octaplas™ Now Available for U.S. Patients (August 29, 2013)